Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer

BACKGROUND: This randomised, open-label, multicenter phase II study compared progression-free survival (PFS) of S-1 plus oxaliplatin (SOX) with that of S-1 alone in patients with gemcitabine-refractory pancreatic cancer. METHODS: Patients with confirmed progressive disease following the first-line t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohkawa, S, Okusaka, T, Isayama, H, Fukutomi, A, Yamaguchi, K, Ikeda, M, Funakoshi, A, Nagase, M, Hamamoto, Y, Nakamori, S, Tsuchiya, Y, Baba, H, Ishii, H, Omuro, Y, Sho, M, Matsumoto, S, Yamada, N, Yanagimoto, H, Unno, M, Ichikawa, Y, Takahashi, S, Watanabe, G, Wakabayashi, G, Egawa, N, Tsuda, M, Hosotani, R, Hamada, C, Hyodo, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453667/
https://www.ncbi.nlm.nih.gov/pubmed/25880004
http://dx.doi.org/10.1038/bjc.2015.103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453667/
https://www.ncbi.nlm.nih.gov/pubmed/25880004
http://dx.doi.org/10.1038/bjc.2015.103

Ejemplares similares